The global biosurgery market is estimated to be valued at USD 19,115.8 Mn in 2026 and is projected to grow at a compound annual growth rate (CAGR) of 6.6% during the forecast period (2026-2033), reaching USD 29,899.4 Mn by 2033. This growth can be attributed rising number of surgical procedures, increasing prevalence of chronic diseases and trauma cases, and growing demand for minimally invasive surgeries.
The global biosurgery market is poised to exhibit steady growth during the forecast period. This is due to rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, growing adoption of advanced hemostatic and sealant products. Similarly, rising volume of surgical procedures worldwide and continuous technological advancements in biosurgical products are supporting market expansion.
Rising number of road accidents, sports injuries, trauma cases, and elective surgeries is fueling demand for effective blood-loss management and wound closure products. Biosurgery products are increasingly preferred over traditional sutures and staples because they improve surgical efficiency and reduce complications.
Growing adoption of surgical sealants and adhesives is a key growth-shaping trend in the biosurgery market. Surgical sealants and adhesives are among the fastest-growing segments because they provide superior tissue adhesion, lower infection risks, and reduced operating time compared to conventional closure methods.
Increasing Prevalence of Chronic Diseases: Rising prevalence of chronic conditions such as cardiovascular diseases, cancer, diabetes, orthopedic disorders, and obesity is increasing the number of surgical interventions worldwide. For instance, according to the This, in turn, is providing a strong impetus for the growth of the biosurgery market. Patients with chronic conditions often require enhanced wound management and tissue regeneration solutions, thereby boosting the demand for biosurgery products.
Advancements in Biomaterials and Tissue Engineering: Continuous innovations in biomaterials, regenerative medicine, and tissue engineering are paving the way for the development of next-generation biosurgery products with improved biocompatibility, faster healing capabilities, and enhanced surgical precision. Manufacturers are increasingly developing synthetic and hybrid sealants, sprayable fibrin glues, hydrogels, and bioactive scaffolds for a wider range of surgical applications. These advancements are expected to support the growth of the biosurgery market in the coming years.
|
Current Event |
Description and its Impact |
|
FDA warns of shortages in neurosurgical sponges and patties (2026) |
|
|
Growing surgical procedure volumes worldwide |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
According to Coherent Market Insights’ latest biosurgery market analysis, haemostatic agents segment is set to lead the market with a share of 34% in 2026. This dominance can be attributed to rising number of surgical procedures worldwide, growing prevalence of trauma and chronic diseases, and increasing demand for effective blood loss management during surgeries.
Haemostatic agents are widely used in cardiovascular, orthopedic, neurological, and general surgical procedures due to their ability to rapidly control bleeding and improve patient outcomes. In addition, technological advancements in advanced haemostatic products, including thrombin-based agents, gelatin sponges, oxidized regenerated cellulose, and combination haemostats, are also boosting segment growth.

To learn more about this report, Request Free Sample
By disease type, general surgery segment is expected to dominate the global biosurgery market, accounting for a revenue share of more than 32% in 2026. This is attributable to the rising volume of surgical procedures worldwide, increasing adoption of hemostatic agents and sealants in complex surgeries, and growing preference for minimally invasive surgical techniques.
Biosurgery products are widely utilized in general surgeries to control bleeding, prevent tissue leakage, and accelerate wound healing, thereby improving patient outcomes and reducing post-operative complications. In addition, increasing prevalence of chronic diseases, expanding geriatric population, and advancements in surgical technologies are expected to boost growth of the target segment during the forthcoming period.

To learn more about this report, Request Free Sample
North America is expected to dominate the global biosurgery market with a 40% share in 2026. This can be attributed to advanced healthcare infrastructure, high surgical procedure volumes, and growing adoption of minimally invasive surgeries. Increasing prevalence of chronic diseases such as cardiovascular disorders, cancer, and obesity is also fueling demand for biosurgery products like surgical sealants, hemostats, and adhesion barriers.
According to the U.S. CDC, approximately 51.4 million inpatient procedures, including many surgical procedures, are performed annually in the United States. The large volume of surgeries significantly boosts demand for biosurgery products used for bleeding control, tissue sealing, and wound healing during surgical procedures.
Asia Pacific is forecast to emerge as a hotbed for manufacturers of biosurgery products during the forecast period, capturing a global market share of 24% in 2026. This is mainly due to a rapidly aging population, rising healthcare expenditure, and increasing adoption of minimally invasive and robotic-assisted surgeries.
The aging population is more prone to degenerative diseases and surgeries such as joint replacements, cardiovascular procedures, and reconstructive surgeries. Older patients also require faster healing and reduced post-operative complications, which supports adoption of biosurgical materials and biologic sealants. Thus, expanding geriatric population is expected to boost growth of the Asia Pacific biosurgery market during the forecast period.
The United States is expected to remain a leading market for biosurgery products during the forecast period. This is mostly due to increasing prevalence of chronic diseases and growing adoption of minimally invasive procedures. According to the American College of Surgeons, millions of surgical procedures are performed annually in the United States, creating strong demand for biosurgery products such as hemostats, surgical sealants, and adhesion barriers for effective bleeding management and wound healing.
China’s biosurgery market is poised to witness robust growth during the assessment period owing to rapid expansion of healthcare infrastructure, rising surgical procedures, and increasing aging population. According to China’s National Bureau of Statistics (2025 release), the country’s population aged 60 years and above reached 323.4 million, accounting for 23.0% of the total population. This demographic trend is significantly increasing the prevalence of age-related disorders and surgical interventions, thereby driving demand for biosurgery products used in orthopedic, cardiovascular, and general surgeries.
Some of the major players in Biosurgery Market are Betatech Medical, Hemostasis LLC, CryoLife Inc., CSL Limited, Medtronic PLC, Johnson & Johnson, B.Braun Melsungen AG, Baxter International Inc., Integra Lifesciences Holdings Corporation, and Becton, Dickinson and Company (CR Bard), among others.
Leading companies in the biosurgery market are adopting various strategies to boost their revenue as well as gain a competitive edge over the industry. These include AI-enabled surgical innovations, strategic partnerships, acquisitions, robotic surgery expansion, and new product launches.
For example, in 2025, Companies are also focusing on minimally invasive and robotic-assisted surgery technologies through collaborations and acquisitions.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 19,115.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.6% | 2033 Value Projection: | USD 29,899.4 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Betatech Medical, Hemostasis LLC, CryoLife Inc., CSL Limited, Medtronic PLC, Johnson & Johnson, B.Braun Melsungen AG, Baxter International Inc., Integra Lifesciences Holdings Corporation, and Becton, Dickinson and Company (CR Bard), among others. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients